AtriCure Reports Third Quarter 2013 Financial Results *Revenue of $20.1 million – up 24.8%; 24.0% constant currency *U.S. sales of $15.8 million – up 28.1% *International sales of $4.3 million – up 14.2%; 10.8% constant currency Business Wire WEST CHESTER, Ohio -- October 29, 2013 AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced financial results for the third quarter of 2013. “We are pleased with our performance in the third quarter. Our results reflect our third consecutive quarter of double digit year over year revenue growth, driven by overall strength and our U.S. business which was up 28% versus the prior year. We are seeing the results of our training and education efforts in capturing market share, and we are gaining momentum with the AtriClip,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “Based on continued strength across all of our product lines, we are updating our outlook for 2013 to reflect anticipated revenue growth of 14% from 2012.” Third Quarter 2013 Financial Results Revenue for the third quarter of 2013 was $20.1 million, an increase of $4.0 million or 24.8% (24.0% on a constant currency basis), compared to third quarter 2012 revenue. Domestic revenue increased 28.1% to $15.8 million, driven by strong sales of ablation-related open-heart products and AtriClip products. International revenue was $4.3 million, an increase of $0.5 million or 14.2% (10.8% on a constant currency basis) when compared to $3.8 million for the third quarter of 2012. International revenue growth was driven primarily by increased sales to direct customers and certain distributors. Gross profit for the third quarter of 2013 was $14.7 million compared to $11.5 million for the third quarter of 2012. Gross margin for the third quarter of 2013 and 2012 was 72.9% and 71.6%, respectively. The increase in gross margin was due primarily to volume-driven leverage of manufacturing overhead expenses, a higher mix of domestic sales and the strong performance of the new AtriClip Pro product. Operating expenses for the third quarter of 2013 increased 22.9%, or $3.2 million, compared to the third quarter of 2012. The increase in operating expenses was driven primarily by an increase in selling, marketing and training expenses. Loss from operations for the third quarter of 2013 was $2.6 million compared to $2.5 million for the third quarter of 2012. Net loss per share was $0.13 for the third quarter of 2013 and $0.16 for the third quarter of 2012. Cash, cash equivalents and investments were $34.4 million at September 30, 2013 and cash provided by operations during the third quarter of 2013 was $0.7 million. 2013 Guidance Management projects that 2013 revenue will be approximately $80.0 million, an increase of 14% from 2012. This compares to the previous outlook for 2013 revenue in the range of $77.0 - $78.5 million, an increase of 10% - 12% from 2012. Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $4.5 to $5.5 million including the impact of the medical device excise tax which is estimated to be in the range of $0.6 - $0.8 million for 2013. Management expects to continue making investments targeted at future revenue growth. Conference Call AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, October 29, 2013 to discuss its third quarter 2013 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure’s corporate website at www.atricure.com. You may also access this call through an operator by calling (888) 713-4211 for domestic callers and (617) 213-4864 for international callers at least 15 minutes prior to the call start time using reservation code 83850169. The webcast will be available on AtriCure’s website and a telephonic replay of the call will also be available through November 29, 2013. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. The reservation code is 29085641. About AtriCure, Inc. AtriCure, Inc. is a leading atrial fibrillation solutions partner, providing innovative products, professional education and support for clinical science to reduce the economic and social burden of atrial fibrillation. AtriCure's Synergy Ablation System is the first and only device approved by the Food and Drug Administration (FDA) for the surgical treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open heart procedures concomitantly (simultaneously). AtriCure's AtriClip™ Left Atrial Appendage (LAA) occlusion device is the most widely implanted device for LAA management worldwide.Afib affects more than two million people worldwide and is estimated to cost more than $6.5 billion annually in healthcare expenses. The number affected by Afib is expected to grow to 12 million by 2050. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates (including projections and guidance), other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Use of Non-GAAP Financial Measures To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles, or GAAP, AtriCure uses certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures provide an indication of performance excluding certain items. Our management believes that in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing operations and our management believes that the excluded items are typically not reflective of our ongoing core business operations. Further, management uses results of operations before these excluded items as a basis for its strategic planning. The non-GAAP financial measures used by AtriCure may not be the same or calculated the same as those used by other companies. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Amounts) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2013 2012 2013 2012 Revenue: Open-heart $ 9,637 $ 7,656 $ 27,912 $ 24,529 Minimally 3,486 3,112 10,129 9,324 invasive AtriClip 2,709 1,593 7,884 5,113 Total United 15,832 12,361 45,925 38,966 States International 4,314 3,778 14,080 12,917 Total revenue 20,146 16,139 60,005 51,883 Cost of revenue 5,461 4,590 16,111 14,871 Gross profit 14,685 11,549 43,894 37,012 Operating expenses: Research and development 3,237 2,905 9,792 9,180 expenses Selling, general and 14,062 11,173 40,155 33,178 administrative expenses Total operating 17,299 14,078 49,947 42,358 expenses Loss from (2,614 ) (2,529 ) (6,053 ) (5,346 ) operations Other expense (130 ) (27 ) (415 ) (148 ) Loss before income tax (2,744 ) (2,556 ) (6,468 ) (5,494 ) expense Income tax (4 ) (11 ) (14 ) (20 ) expense Net loss $ (2,748 ) $ (2,567 ) $ (6,482 ) $ (5,514 ) Basic and diluted net $ (0.13 ) $ (0.16 ) $ (0.32 ) $ (0.34 ) loss per share Weighted average shares used in computing net loss per common share: Basic and 20,725 16,278 20,311 16,143 diluted ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Per Share Amounts) (Unaudited) September 30, December 31, 2013 2012 Assets Current assets: Cash, cash equivalents and short-term $ 29,685 $ 12,000 investments Accounts receivable, net 11,031 9,948 Inventories 7,062 5,718 Other current assets 779 873 Total current assets 48,557 28,539 Property and equipment, net 4,135 3,430 Intangible assets 23 32 Long-term investments 4,678 - Other assets 244 430 Total assets $ 57,637 $ 32,431 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued $ 14,238 $ 10,176 liabilities Current maturities of long-term debt 2,037 2,029 and capital lease obligations Total current liabilities 16,275 12,205 Long-term debt and capital lease 4,922 6,407 obligations Other liabilities 195 1,319 Total liabilities 21,392 19,931 Stockholders' equity: Common stock 21 17 Additional paid-in capital 153,420 123,157 Other comprehensive income 37 77 Accumulated deficit (117,233 ) (110,751 ) Total stockholders' equity 36,245 12,500 Total liabilities and stockholders' $ 57,637 $ 32,431 equity ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands) (Unaudited) Nine Months Ended September 30, 2013 2012 Cash flows from operating activities: Net loss $ (6,482 ) $ (5,514 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation expense 2,072 2,941 Depreciation and amortization of 1,465 1,520 intangible assets Amortization of deferred financing 69 81 costs Loss (gain) on disposal of equipment 30 (12 ) Amortization/accretion on investments (4 ) 16 Change in allowance for doubtful (14 ) (21 ) accounts Changes in assets and liabilities Accounts receivable (1,049 ) 125 Inventories (1,313 ) (319 ) Other current assets 117 122 Accounts payable and accrued 2,744 (510 ) liabilities Other non-current assets and 207 (174 ) liabilities Net cash used in operating activities (2,158 ) (1,745 ) Cash flows from investing activities: Purchases of available-for-sale (9,186 ) (8,538 ) securities Maturities of available-for-sale 4,900 8,100 securities Purchases of property and equipment (1,930 ) (2,372 ) Net proceeds from the sale of 2 24 equipment Net cash used in investing activities (6,214 ) (2,786 ) Cash flows from financing activities: Net proceeds from sale of stock 26,872 - Proceeds from debt borrowings - 10,000 Payments on debt and capital leases (1,547 ) (7,568 ) Payment of debt fees (99 ) (78 ) Proceeds from stock option exercises 1,277 562 Shares repurchased for payment of (279 ) (372 ) taxes on stock awards Proceeds from issuance of common stock 326 372 under employee stock purchase plan Net cash provided by financing 26,550 2,916 activities Effect of exchange rate changes on (110 ) 59 cash and cash equivalents Net increase (decrease) in cash and 18,068 (1,556 ) cash equivalents Cash and cash equivalents - beginning 7,753 9,759 of period Cash and cash equivalents - end of $ 25,821 $ 8,203 period ATRICURE, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS (In Thousands) (Unaudited) Reconciliation of Non-GAAP Adjusted Loss (Adjusted EBITDA) Three Months Ended September Nine Months Ended 30, September 30, 2013 2012 2013 2012 Net loss, as $ (2,748 ) $ (2,567 ) $ (6,482 ) $ (5,514 ) reported Income tax 4 11 14 20 expense Other expense 130 27 415 148 (a) Depreciation and 508 467 1,465 1,520 amortization expense Share-based compensation 734 1,111 2,072 2,941 expense Non-GAAP adjusted loss $ (1,372 ) $ (951 ) $ (2,516 ) $ (885 ) (adjusted EBITDA) Three Months Ended September Nine Months Ended 30, September 30, (a) Other 2013 2012 2013 2012 includes: Net interest $ (121 ) $ (187 ) $ (420 ) $ (609 ) expense Grant income - 117 - 379 Gain (loss) due to 17 (42 ) 73 (77 ) exchange rate fluctuation Non-employee stock option (26 ) 85 (68 ) 159 (expense) income Other expense $ (130 ) $ (27 ) $ (415 ) $ (148 ) Contact: AtriCure, Inc. Andy Wade, 513-755-4564 Vice President and Chief Financial Officer email@example.com or Investor Relations Contact Westwicke Partners Lynn Pieper, 415-202-5678 firstname.lastname@example.org
AtriCure Reports Third Quarter 2013 Financial Results
Press spacebar to pause and continue. Press esc to stop.